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Globally, the number of deaths from cancer exceeds the number of deaths from human immunodeficiency virus (HIV), malaria, and tuberculosis combined. Global cancer rates are rising dramatically with a predicted 23.6 million new cases per year worldwide by 2030. 2 More than 50% of all cancer cases and 65% of related deaths occur in low and middle-income countries (LMICs), where cancer is a primary cause of early death, and the prevalence has been steadily increasing partly due to population aging, adaptation of western lifestyles, and improved control of infectious diseases. 3, 4 Worldwide, cervical cancer is the fourth most common cancer among women. 5 However, 85% of cervical cancer diagnoses and related deaths occur in women living in LMICs. 6 Cervical cancer is now relatively uncommon in the United States and other high-income countries due to introduction of the Papanicolaou (Pap) test coupled with the introduction of organized screening programs which together have led to a 70% decrease in cervical cancer incidence and mortality rates over the last 60 years. Cervical cancer is currently the 11th most common cancer among women in the United States, with an incidence of 7.5 per 100 000 women and a mortality of 2.3 per 100 000 nationally between 2009 and 2013. 7 However, it continues to be the first or second leading cause of cancer-related death among women in many LMICs, with Latin America and the Caribbean region accounting for almost 12% of the world's cervical cancer deaths. 8 In Central and South America, cervical cancer incidence and mortality rates vary widely. For example, it is the leading cause of cancer-related deaths among women in French Guyana, El Salvador, and Bolivia; and in contrast, it is the sixth cause of cancer deaths among women in Chile and fourth cause in Costa Rica and Cuba. 9, 10 Cervical cancer is a preventable disease with excellent primary and secondary prevention strategies. Virtually all cases of cervical cancer are caused by persistent infection with high-risk types of the human papillomavirus (HPV). HPV is the most common sexually transmitted disease worldwide and approximately 80% of women and men will be infected with HPV at some point in their lifetime. The initial infection usually occurs during adolescence or early adulthood, with the majority of women clearing the infection within 18-24 months. However, in 3-5% of women, the HPV infection persists and they develop significant pre-invasive disease, and in <1% invasive cancer develops. HPV infection is also the causative agent of other malignancies including cancer of the oropharynx, anus, penis, vulva, and vagina. Despite the availability of HPV vaccines, cervical cancer screening will remain necessary for the foreseeable future due to poor vaccine uptake and because the existing vaccines do not treat pre-existing HPV infections and related disease. Two to three generations of women will not benefit from the HPV vaccine as they were beyond the recommended age when the vaccines became available and/or they were already been exposed to HPV. The aim of this paper is to focus on three issues impacting cervical cancer prevention and treatment, regardless of geography, that can be addressed using evidence based strategies to reduce cervical cancer incidence and mortality rates in Latin America. These include:
(1) lack of access to screening and follow-up because of limited medical/clinical infrastructure; (2) high rates of morbidity and mortality due to unsafe or unnecessary surgical procedures; and (3) lack of consistency in national cancer control plans, policies, and implementation of clinical guidelines.
| ADDRESSING CLINICAL CAPACITY
There are many models of capacity building in underserved areas Project ECHO is different from telemedicine, in which the specialist assumes the care of the patient, but instead, involves telementoring, in which the community clinician retains responsibility for managing the patient, operating with increasing independence as his/her skills and self-efficacy grow. Clinicians in underserved areas learn from the specialists and from each other, and specialists learn from the community providers. This is a many-to-many approach, as opposed to the approach of traditional telemedicine. 14 The ECHO telementoring program is complemented by hands on training for diagnostic and therapeutic surgical procedures in the low resource areas such as colposcopy and LEEP courses held locally. In parallel, we are performing several collaborative research studies to evaluate improved methods for cervical cancer screening and treatment including low-cost mobile colposcopes, alternatives to traditional cryotherapy, 15 and point of care
cervical dysplasia diagnostic tools such as the high-resolution microendoscopy (HRME) developed by Rice University. 
| IMPROVING CERVICAL CANCER OUTCOMES BY IMPROVING ACCESS TO SAFE SURGERY
According to the Lancet Commission on Surgery, in the absence of widely available surgical care in LMICs, case-fatality rates are high for cervical cancer which is considered a common, easily treatable condition. 18 Safe surgery processes, such as checklists, are not widely An alternative to chemoradiation is the use of neoadjuvant chemotherapy followed by surgery. Previous reports have shown this strategy to achieve an objective response rate of 84% and overall survival of 773% in the United States. 20 This strategy was also recently evaluated in the National Institute of Neoplastic Diseases (INEN) in Peru with promising preliminary results. 21 For these reasons, neoadjuvant chemotherapy followed by surgery should continue to be evaluated as an alternative in areas where safe and effective chemoradition is not available. 
